FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2940327706> ?p ?o ?g. }

• W2940327706 endingPage "1492" @default.
• W2940327706 startingPage "1483" @default.
• W2940327706 abstract "Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.Lp(a) was measured in 25 096 patients in the FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), a randomized trial of evolocumab versus placebo in patients with established atherosclerotic cardiovascular disease (median follow-up, 2.2 years). Cox models were used to assess the independent prognostic value of Lp(a) and the efficacy of evolocumab for coronary risk reduction by baseline Lp(a) concentration.The median (interquartile range) baseline Lp(a) concentration was 37 (13-165) nmol/L. In the placebo arm, patients with baseline Lp(a) in the highest quartile had a higher risk of coronary heart disease death, myocardial infarction, or urgent revascularization (adjusted hazard ratio quartile 4: quartile 1, 1.22; 95% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol. At 48 weeks, evolocumab significantly reduced Lp(a) by a median (interquartile range) of 26.9% (6.2%-46.7%). The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking evolocumab was moderately positively correlated ( r=0.37; 95% CI, 0.36-0.39; P<0.001). Evolocumab reduced the risk of coronary heart disease death, myocardial infarction, or urgent revascularization by 23% (hazard ratio, 0.77; 95% CI, 0.67-0.88) in patients with a baseline Lp(a) >median, and by 7% (hazard ratio, 0.93; 95% CI, 0.80-1.08; P interaction=0.07) in those ≤median. Coupled with the higher baseline risk, the absolute risk reductions, and number needed to treat over 3 years were 2.49% and 40 versus 0.95% and 105, respectively.Higher levels of Lp(a) are associated with an increased risk of cardiovascular events in patients with established cardiovascular disease irrespective of low-density lipoprotein cholesterol. Evolocumab significantly reduced Lp(a) levels, and patients with higher baseline Lp(a) levels experienced greater absolute reductions in Lp(a) and tended to derive greater coronary benefit from PCSK9 inhibition.URL: https://www.clinicaltrials.gov . Unique identifier: NCT01764633." @default.
• W2940327706 created "2019-04-25" @default.
• W2940327706 creator A5005451442 @default.
• W2940327706 creator A5011948462 @default.
• W2940327706 creator A5017005943 @default.
• W2940327706 creator A5022099697 @default.
• W2940327706 creator A5030057930 @default.
• W2940327706 creator A5032676392 @default.
• W2940327706 creator A5046367811 @default.
• W2940327706 creator A5048145643 @default.
• W2940327706 creator A5049396220 @default.
• W2940327706 creator A5064701809 @default.
• W2940327706 creator A5066653118 @default.
• W2940327706 creator A5067039078 @default.
• W2940327706 creator A5067797353 @default.
• W2940327706 creator A5077862111 @default.
• W2940327706 creator A5081557648 @default.
• W2940327706 creator A5081943616 @default.
• W2940327706 creator A5083340275 @default.
• W2940327706 creator A5085573148 @default.
• W2940327706 creator A5086317157 @default.
• W2940327706 creator A5087033748 @default.
• W2940327706 date "2019-03-19" @default.
• W2940327706 modified "2023-10-17" @default.
• W2940327706 title "Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk" @default.
• W2940327706 cites W1708837772 @default.
• W2940327706 cites W1856460279 @default.
• W2940327706 cites W1950462993 @default.
• W2940327706 cites W1990204315 @default.
• W2940327706 cites W1994699782 @default.
• W2940327706 cites W2022756739 @default.
• W2940327706 cites W2032867296 @default.
• W2940327706 cites W2040690967 @default.
• W2940327706 cites W2042583787 @default.
• W2940327706 cites W2071048602 @default.
• W2940327706 cites W2098230963 @default.
• W2940327706 cites W2098890974 @default.
• W2940327706 cites W2104355263 @default.
• W2940327706 cites W2106951652 @default.
• W2940327706 cites W2168972442 @default.
• W2940327706 cites W2253359374 @default.
• W2940327706 cites W2313206757 @default.
• W2940327706 cites W2338134757 @default.
• W2940327706 cites W2522418769 @default.
• W2940327706 cites W2526246517 @default.
• W2940327706 cites W2543585581 @default.
• W2940327706 cites W2563852152 @default.
• W2940327706 cites W2590841352 @default.
• W2940327706 cites W2592174078 @default.
• W2940327706 cites W2596179513 @default.
• W2940327706 cites W2785510370 @default.
• W2940327706 cites W2789891083 @default.
• W2940327706 cites W2791615591 @default.
• W2940327706 cites W2808216713 @default.
• W2940327706 cites W2809135070 @default.
• W2940327706 cites W2809552245 @default.
• W2940327706 cites W2883904532 @default.
• W2940327706 cites W98619866 @default.
• W2940327706 doi "https://doi.org/10.1161/circulationaha.118.037184" @default.
• W2940327706 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30586750" @default.
• W2940327706 hasPublicationYear "2019" @default.
• W2940327706 type Work @default.
• W2940327706 sameAs 2940327706 @default.
• W2940327706 citedByCount "482" @default.
• W2940327706 countsByYear W29403277062019 @default.
• W2940327706 countsByYear W29403277062020 @default.
• W2940327706 countsByYear W29403277062021 @default.
• W2940327706 countsByYear W29403277062022 @default.
• W2940327706 countsByYear W29403277062023 @default.
• W2940327706 crossrefType "journal-article" @default.
• W2940327706 hasAuthorship W2940327706A5005451442 @default.
• W2940327706 hasAuthorship W2940327706A5011948462 @default.
• W2940327706 hasAuthorship W2940327706A5017005943 @default.
• W2940327706 hasAuthorship W2940327706A5022099697 @default.
• W2940327706 hasAuthorship W2940327706A5030057930 @default.
• W2940327706 hasAuthorship W2940327706A5032676392 @default.
• W2940327706 hasAuthorship W2940327706A5046367811 @default.
• W2940327706 hasAuthorship W2940327706A5048145643 @default.
• W2940327706 hasAuthorship W2940327706A5049396220 @default.
• W2940327706 hasAuthorship W2940327706A5064701809 @default.
• W2940327706 hasAuthorship W2940327706A5066653118 @default.
• W2940327706 hasAuthorship W2940327706A5067039078 @default.
• W2940327706 hasAuthorship W2940327706A5067797353 @default.
• W2940327706 hasAuthorship W2940327706A5077862111 @default.
• W2940327706 hasAuthorship W2940327706A5081557648 @default.
• W2940327706 hasAuthorship W2940327706A5081943616 @default.
• W2940327706 hasAuthorship W2940327706A5083340275 @default.
• W2940327706 hasAuthorship W2940327706A5085573148 @default.
• W2940327706 hasAuthorship W2940327706A5086317157 @default.
• W2940327706 hasAuthorship W2940327706A5087033748 @default.
• W2940327706 hasBestOaLocation W29403277061 @default.
• W2940327706 hasConcept C119060515 @default.
• W2940327706 hasConcept C126322002 @default.
• W2940327706 hasConcept C142724271 @default.
• W2940327706 hasConcept C164705383 @default.
• W2940327706 hasConcept C204787440 @default.
• W2940327706 hasConcept C207103383 @default.
• W2940327706 hasConcept C27081682 @default.

• next